The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.
We recently published a list of Jim Cramer Latest Portfolio: 10 Stocks to Buy and Sell. Since Axsome Therapeutics Inc (NASDAQ:AXSM) ranks 4th on the list, it deserves a deeper look. Jim Cramer in his latest program talked about how the China factor is affecting US stocks. He said that companies that have exposure to China are […]
AXSM earnings call for the period ending June 30, 2024.